Aberrant fibroblast growth factor receptor signaling in bladder and other cancers

Christine Chaffer, Bonnie Dopheide, Pierre Savagner, Erik W Thompson, Elizabeth Williams

Research output: Contribution to journalArticleResearchpeer-review

54 Citations (Scopus)

Abstract

Fibroblast growth factors (FGFs) are potent mitogens, morphogens, and inducers of angiogenesis, and FGF signaling governs the genesis of diverse tissues and organs from the earliest stages. With such fundamental embryonic and homeostatic roles, it follows that aberrant FGF signaling underlies a variety of diseases. Pathological modifications to FGF expression are known to cause salivary gland aplasia and autosomal dominant hypophosphatemic rickets, while mutations in FGF receptors (FGFRs) result in a range of skeletal dysplasias. Anomalous FGF signaling is also associated with cancer development and progression. Examples include the overexpression of FGF2 and FGF6 in prostate cancer, and FGF8 overexpression in breast and prostate cancers. Alterations in FGF signaling regulators also impact tumorigenesis, which is exemplified by the down-regulation of Sprouty 1, a negative regulator of FGF signaling, in
Original languageEnglish
Pages (from-to)831 - 842
Number of pages12
JournalDifferentiation
Volume75
Issue number9
DOIs
Publication statusPublished - 2007

Cite this

Chaffer, C., Dopheide, B., Savagner, P., Thompson, E. W., & Williams, E. (2007). Aberrant fibroblast growth factor receptor signaling in bladder and other cancers. Differentiation, 75(9), 831 - 842. https://doi.org/10.1111/j.1432-0436.2007.00210.x